NCT00343681CompletedPhase 2
Immunogenicity and Safety of the Inactivated, Split-Virion Influenza Vaccine, Northern Hemisphere 2006-2007 Formulation (Intramuscular Route)
Sanofi Pasteur, a Sanofi Company2 sites in 2 countries120 target enrollmentStarted: July 2006Last updated:
Conditions
Trial Snapshot
- Phase
- Phase 2
- Status
- Completed
- Enrollment
- 120
- Locations
- 2
- Primary Endpoint
- To provide information concerning the immunogenicity of inactivated influenza vaccine (split virion)
Study Overview
Brief Summary
This study is designed to generate clinical data as outlined in the Note for Guidance on harmonization requirements for influenza vaccine marketing authorization by the European Medicines Agency.
The objectives of the trial are:
- To evaluate the compliance, in terms of immunogenicity, of the inactivated, split-virion influenza vaccine Northern Hemisphere 2006-2007 formulation with the requirements of the European Medicines Agency
- To describe the safety of the inactivated, split-virion influenza vaccine, Northern Hemisphere 2006-2007 formulation.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •Aged at least 18 years on the day of inclusion
- •Informed consent form signed
- •Able to attend all scheduled visits and to comply with all trial procedures
- •For a woman, inability to bear a child or negative urine pregnancy test at Visit 1
- •For a woman of child-bearing potential: use of an effective method of contraception or abstinence for at least four weeks prior to vaccination and at least three weeks after vaccination.
Exclusion Criteria
- •Febrile illness (oral temperature >=37.5°C) on the day of vaccination
- •Breast-feeding
- •Participation in another clinical trial in the four weeks preceding the trial vaccination
- •Planned participation in another clinical trial during the present trial period
- •Congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding six months, or long-term systemic corticosteroids therapy
- •Systemic hypersensitivity to egg proteins, chick proteins, or to any of the vaccine components, or history of a life-threatening reaction to the trial vaccine or a vaccine containing the same substances
- •Chronic illness at a stage that could interfere with trial conduct or completion
- •Current abuse of alcohol or drug addiction that may interfere with the subject's ability to comply with trial procedures
- •Blood or blood-derived products received in the past three months
- •Any vaccination in the four weeks preceding the trial vaccination
- •Vaccination planned in the three weeks following the trial vaccination
- •Vaccination against influenza in the previous six months
- •Thrombocytopenia or bleeding disorder contraindicating intramuscular vaccination
- •Subject deprived of freedom by an administrative or court order, or in an emergency setting, or hospitalized without his/her consent
Outcomes
Primary Outcomes
To provide information concerning the immunogenicity of inactivated influenza vaccine (split virion)
Time Frame: 21 Days post-vaccination
Secondary Outcomes
No secondary outcomes reported
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 2
A Study of the Immunogenicity and Safety of the 2007-2008 Influenza VaccineOrthomyxoviridae InfectionsInfluenzaNCT00491257Sanofi Pasteur, a Sanofi Company130
Completed
Phase 1
Study on Safety, Tolerability and Immunogenicity of an MVA Vaccine Administered to Healthy SubjectsSmallpoxNCT00189943Bavarian Nordic90
Completed
Phase 3
Study of the EpiVacCorona Vaccine With the Involvement of Volunteers Aged 60 Years and AboveCovid19NCT05021016Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector"150
Completed
Phase 4
Post-Authorization Safety, Tolerability and Immunogenicity Evaluation of HyQvia in Pediatric PIDD SubjectsPrimary Immunodeficiency Diseases (PID)NCT03116347Baxalta now part of Shire42
Completed
Phase 1
Combination Study With MVA BN and DryvaxSmallpoxNCT00082446National Institute of Allergy and Infectious Diseases (NIAID)91